Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 23, 2018 (9 years ago)

Lynparza (olaparib)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Lynparza (olaparib) capsules 50 mg, 112 count bottles, Rx only, Manufactured for: Astra Zeneca Pharmaceuticals LP Wilmington, DE 19850 by: Patheon Pharmaceuticals, Inc. Cincinnati OH 45237 Product of Switzerland NDC 0310-0657-58

Affected NDC 0310-0657-58

Compare with the code on your package — it is the most precise check available.

Recalling firm
AstraZeneca Pharmaceuticals LP
NDC code
0310-0657-58
Origin
DE, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0585-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by AstraZeneca Pharmaceuticals LP

All 2018 recalls
Class I · High risk

BRILINTA (ticagrelor)

Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

Terminated Particulate / foreign matter AstraZeneca Pharmaceuticals, LP NDC 0186-0777-08 D-0958-2017
Class II · Moderate risk

Tudorza Pressair

Defective Delivery System: Some units have actuation counters set to a number other than 60.

Terminated Packaging defect AstraZeneca Pharmaceuticals LP D-0781-2016
Class II · Moderate risk

NEXIUM¿ (esomeprazole magnesium)

Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR tablets.

Terminated Particulate / foreign matter AstraZeneca Pharmaceuticals LP NDC 00186-5020-31 D-1141-2015
Class II · Moderate risk

Merrem I.V.

Presence of Precipitate; potential for incomplete constitution upon addition of diluent.

Terminated Failed specification AstraZeneca Pharmaceuticals LP D-840-2013

Other impurity / degradation recalls from 2018

All impurity / degradation recalls
Class III · Low risk

AMITIZA (lubiprostone)

Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.

Terminated Impurity / degradation Takeda Development Center Americas, Inc. NDC 64764-080-60 D-0286-2019
Class II · Moderate risk

children's allergy relief

Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

Terminated Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. D-0278-2019